ATLAS Biolabs offers molecular genetic services. These services include next-generation sequencing (NGS) and the analysis of microarrays as well as high-quality bioinformatic data analyses upon request. In addition to human samples, we also process biomaterial of common model organisms, such as mouse, rat, zebrafish, Drosophila etc. Furthermore, we analyse DNA and RNA of farm animals, plants (agrigenomics) as well as domestic animals and microorganisms.
ATLAS Biolabs' molecular genetics laboratory is accredited by DAkkS according to DIN EN ISO / IEC 17025:2018. Based upon the DIN EN ISO 9001:2015 standard, we further improved our quality management to demonstrate our competence and guarantee the quality of our services. We offer our test method for quantitative transcriptome analysis from total RNA. The accreditation is valid only for the scope listed in the annex of the accreditation certificate D-PL-21662-01-00.
You have special disease-related questions? We offer exome sequencing from IDT, Illumina and Agilent, or alternatively panels with a focus on disease-relevant target regions. These are derived from the HGMD, OMIM and ClinVar databases and possess significantly higher coverage and significance compared to whole exome sequencing.
The causes of genetic diseases can be identified by digital karyotyping, such as copy number variations (CNV), amplifications, deletions, loss of heterozygosity (LOH) or copy-number-neutral LOH (uniparental disomy). Karyotyping based on oligonucleotides using microarrays is characterised by a very high resolution with distances of a few kilobase (kb) only. Depending on the type of microarray, the probes are located at an average distance of 1 kb. We use technologies from Thermo Fisher Scientific/Affymetrix, such as CytoScan and Agilent Technologies (CGH, SurePrint).
We analyse the DNA of your FFPE material using the OncoScan FFPE assay kit (Thermo Fisher Scientific/Affymetrix). This kit ensures a very high resolution (50-100 kb) of the DNA of more than 900 cancer genes. It also allows the analysis of somatic mutations. The dynamic range is 10 copies or more. The method furthermore allows the genome-wide analysis of copy number variations (CNV) and loss of heterozygosity (LOH).
Our focus is also on genetic variations that are influenced by drug uptake or absorption, distribution, metabolism and excretion (ADME). For these cases, ATLAS Biolabs uses special technologies for the investigation of pharmacogenetically relevant genes and markers (PGx), e.g. the Thermo Fisher Scientific/Axiom PharmacoScan.
Transcriptome analyses provide a better understanding of how the genome is transformed into functional proteins. Their clinical benefit is that they permit expression profiles to be classified, which also constitutes a meaningful contribution to individualised medicine. We offer two powerful technologies for transcriptome analysis: hybridisation-based microarray technology and RNA sequencing.